World Muscle Society 2024 (WMS)

Back

Initial Data From the ACHIEVE Trial of DYNE-101 in Adults With Myotonic Dystrophy Type 1 (DM1) (poster)

View

Initial Data From the DELIVER Trial of DYNE-251 in Males With DMD Mutations Amenable to Exon 51 Skipping (poster)

View

The FORCE™ Platform Achieves Robust and Durable DUX4 Suppression and Improves Muscle Function in a Facioscapulohumeral Muscular Dystrophy Mouse Model (poster)

View

The FORCE™ Platform Enables TfR1-mediated Delivery of Enzyme Replacement Therapy to Muscle and Central Nervous System, Resolving Pompe Pathology in Mice (poster)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.